C-kit mutations in gastrointestinal stromal tumours

Area of Science:

• Gastrointestinal Pathology
• Molecular Oncology
• Surgical Oncology

Background:

• Gastrointestinal stromal tumors (GISTs) are typically identified by CD117 and CD34 expression.
• Assessing the malignant potential of GISTs, particularly from small biopsies, presents diagnostic challenges.
• Emerging research suggests c-kit exon 11 mutations may indicate a poorer prognosis in GISTs.

Purpose of the Study:

• To determine the frequency of c-kit exon 11 mutations in a series of 18 GISTs.
• To evaluate the correlation between c-kit exon 11 mutations and histological assessment of malignant potential in GISTs.

Main Methods:

• Immunoperoxidase staining was used to assess tumor immunophenotype for markers including CD117 and CD34.
• Tumors were histologically classified into low, uncertain, or high malignant potential categories.
• DNA was extracted from tumor tissues, and c-kit exon 11 was amplified by PCR and sequenced.

Main Results:

• C-kit exon 11 mutations were identified in three of 14 confirmed GISTs.
• These mutations included point mutations and a 3-bp deletion.
• All three tumors with exon 11 mutations exhibited high or intermediate malignant potential histologically.

Conclusions:

• In this cohort, c-kit exon 11 mutation analysis showed poor correlation with histological assessment of GIST malignant potential.
• C-kit exon 11 mutation analysis is not a reliable objective marker for predicting poor prognosis in GISTs.
• Further research may be needed to identify reliable prognostic markers for GISTs.